Tioga Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Tioga Pharmaceuticals has been formed to develop asimadoline, to treat pain in patients with irritable bowel syndrome and other gastrointestinal diseases. But unlike in-licensers that seek many shots on goal to balance risk, it is singularly focused on development of this asset.
You may also be interested in...
The A-List: 2005's Trend-Shaping Series A Financings
2005's top early stage venture financings reflect a drive for size and experience on the biotech side, and the demand for less-invasive procedures in the device world. Start-Up lists the top ten Series A rounds of 2005.
The A-List: 2005's Trend-Shaping Series A Financings
2005's top early stage venture financings reflect a drive for size and experience on the biotech side, and the demand for less-invasive procedures in the device world. Start-Up lists the top ten Series A rounds of 2005.
Signs of Movement in IBS Drug Development
Despite Big Pharma's struggles, the availability of compounds developed for other pain indications could energize start-ups' interest in irritable bowel syndrome.